The National Amyotrophic Lateral Sclerosis Registry

Centers for Disease Control and Prevention (CDC) logo

Centers for Disease Control and Prevention (CDC)

Status

Enrolling

Conditions

Amyotrophic Lateral Sclerosis

Study type

Observational

Funder types

Other U.S. Federal agency

Identifiers

NCT01772602
CDC-NCEH/ATSDR-5768

Details and patient eligibility

About

The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS.

Full description

The National ALS Registry's Research Notification System allows person with ALS to participate in clinical trials.

Enrollment

30,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

- U.S. citizens 18 years of age or older

Exclusion criteria

-

Trial contacts and locations

1

Loading...

Central trial contact

Kevin Horton, DrPH, MSPH; Paul Mehta, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems